

PROGRESSIVE MS TRIALS

Updated May 2017. This list highlights notable trials in progressive MS but is not inclusive of all studies.

Abbreviations Key:

ECTRIMS – European Committee of Treatment and Research in MS

IM – intramuscular, injected into muscle

IV – IV, injected into vein

MED – medical therapy, including medications and medical procedures

PP – primary progressive

REHAB – rehabilitation intervention

RR – relapsing-remitting

SC – subcutaneous, injected under the skin

SP – secondary progressive

AGENT	TYPE OF INTER-VENTION	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW THERAPY IS GIVEN	TYPE OF MS/NUMBER OF SUBJECTS	STATUS/RESULTS
ACTHAR® GEL (REPOSITORY CORTICOTROPIN INJECTION)	MED	slow progression	reduces inflammation in central nervous system	SC	SP, PP/100	Recruiting; read more https://clinicaltrials.gov/ct2/show/NCT01950234
ANDROGRAPHOLIDES (HERBACEOUS PLANT, INNO-BIOSCIENCE SPA)	MED	slow progression of brain tissue volume loss	may protect nerves from damage	oral	SP/60	Ongoing, not recruiting, per communication with investigator.

AGENT	TYPE OF INTERVENTION	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW THERAPY IS GIVEN	TYPE OF MS/NUMBER OF SUBJECTS	STATUS/RESULTS
BIIB033 (ANTI-LINGO-1)	MED	assess efficacy, safety, tolerability, and pharmacokinetics, when used with Avonex	may repair nerve cells	IV	RR, SP/419	Completed, did not meet primary endpoint. Read more: http://www.nationalmssociety.org/About-the-Society/News/%E2%80%8BResults-Announced-from-Phase-2-Myelin-Repair-Tria
DIMETHYL FUMARATE (TECFIDERA®, BIOGEN)	MED	evaluate safety and effectiveness	Immune-modulatory, may protect nerve cells	oral	PP/90	Recruiting; read more https://clinicaltrials.gov/ct2/show/NCT02959658
DOMPERIDONE	MED	prevent worsening of walking	increases prolactin, which may promote myelin repair	oral	SP/62	Recruiting; read more https://clinicaltrials.gov/ct2/show/NCT02308137
EPIGALLO-CATECHIN-GALLATE (SUNPHENON®, TAIYO INTERNATIONAL FOOD)	MED	determine effects on brain tissue volume loss	may interfere with T cell growth and function, and protect against neuronal injury (Sunphenon)	oral	SP, PP/60	Completed, awaiting publication of results. Read more http://clinicaltrials.gov/ct2/show/NCT00799890

AGENT	TYPE OF INTER-VENTION	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW THERAPY IS GIVEN	TYPE OF MS/NUMBER OF SUBJECTS	STATUS/RESULTS
ESTRIOL	MED	improve cognition	may improve nerve impulse transmission.	oral	RR,SP,PP /64	Recruiting; read more: http://clinicaltrials.gov/show/NCT01466114
EYE MOVEMENT RETRAINING	REHAB	improve mobility	may improve walking and balancing	eye movement retraining	SP,PP/30	Funded by the National MS Society jointly with other International Progressive MS Alliance members. Completed, Oculomotor training can improve eye hand co-ordination but not clinical functional measures. Read more http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146627/jonathan.marsden.oculomotor.re-training.in.people.with.progressive.multiple.html?f=m3
FUNCTIONAL ELECTRICAL STIMULATION	REHAB	improve walking	low-level electrical impulses to the peroneal nerve signal leg muscles to lift foot	FES cycling	SP/20	Recruiting; read more https://clinicaltrials.gov/ct2/show/NCT01647321
GAIT TRAINING	REHAB	improve walking	Electro-mechanically-assisted gait training system	G-EO system	SP,PP/20	Ongoing, no further information available. Funded by the National MS Society

AGENT	TYPE OF INTER-VENTION	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW THERAPY IS GIVEN	TYPE OF MS/NUMBER OF SUBJECTS	STATUS/RESULTS
GZ402668 (NEXT GENERATION ANTI-CD52 ANTIBODY, SANOFI GENZYME)	MED	test safety and tolerability of sub-cutaneous and intravenous administration	targets CD52 antigen expressed on B and T cells	SC, IV	SP, PP/48	Completed, awaiting publication of results. Read more https://clinicaltrials.gov/ct2/show/NCT02282826
HYDROXY-CHLOROQUINE	MED	improve walking	decreases activity of microglia	oral	PP/35	Recruiting; read more https://clinicaltrials.gov/ct2/show/NCT02913157
IBUDILAST	MED	stop progression	may protect nervous system	oral	SP, PP/250	Ongoing, not recruiting; read more http://clinicaltrials.gov/ct2/show/NCT01982942
IDEBENONE	MED	determine effect on disease activity	acts as a potent antioxidant; potentially also anti-inflammatory	oral	PP/82	Ongoing, not recruiting. Read more https://clinicaltrials.gov/show/NCT00950248
LAQUINIMOD (TEVA PHARMACEUTICAL INDUSTRIES AND ACTIVE BIOTECH)	MED	reduce brain tissue volume loss	Immune-modulatory	oral	PP/375	Ongoing, not recruiting, read more https://clinicaltrials.gov/ct2/show/NCT02284568 . (Higher dose discontinued due to occurrence of cardiovascular events, per company press release, January 4, 2016.)

AGENT	TYPE OF INTER-VENTION	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW THERAPY IS GIVEN	TYPE OF MS/NUMBER OF SUBJECTS	STATUS/RESULTS
LIPOIC ACID	MED	determine effects on protecting the brain and slowing disability	activates cAMP signaling pathways	oral	SP/56	Completed, safe and tolerated, and reduced brain atrophy in lipoic acid group. Read more http://www.neurology.org/content/86/16_Supplement/P1.373
MASITINIB (AB SCIENCE)	MED	determine safety and effectiveness in reducing disease activity	inhibits the survival, migration and activity of mast cells	oral	SP,PP/450	Recruiting; per communication with primary investigator.
MIS416 (INNATE IMMUNOTHERAPEUTICS)	MED	improve neuromuscular function	microparticle derived from bacteria that stimulates immune response	IV	SP/90	Ongoing, not recruiting, read more https://clinicaltrials.gov/ct2/show/NCT02228213
MODIFIED STORY MEMORY TECHNIQUE	REHAB	reduce new learning and memory deficits	helps people to learn new information and remember older information using imagery and context	cognitive rehabilitation	SP,PP/48	Funded by the National MS Society jointly with other International Progressive MS Alliance members. No further information available.

AGENT	TYPE OF INTER-VENTION	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW THERAPY IS GIVEN	TYPE OF MS/NUMBER OF SUBJECTS	STATUS/RESULTS
MS SMART (THREE THERAPIES WITH NERVE-PROTECTING POTENTIAL: FLUOXETINE, AMILORIDE, AND RILUZOLE)	MED	slow or stop MS progression	may protect nerves from damage	oral	SP/440	Ongoing, not recruiting, read more http://clinicaltrials.gov/ct2/show/NCT01910259
NEUROVAX™ (TCR PEPTIDE VACCINE, IMMUNE RESPONSE BIOPHARMA)	MED	determine effect on disease activity	enhances regulatory T cells and regulates disease-causing T cells	IM	SP/200	Not yet recruiting, read more https://clinicaltrials.gov/ct2/show/NCT02057159
NEUROVAX™ (TCR PEPTIDE VACCINE, IMMUNE RESPONSE BIOPHARMA)	MED	slow or stop MS progression	enhances regulatory T cells and regulates disease-causing T cells	IM	SP/150	Not yet recruiting, read more https://clinicaltrials.gov/ct2/show/NCT02149706

AGENT	TYPE OF INTER-VENTION	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW THERAPY IS GIVEN	TYPE OF MS/NUMBER OF SUBJECTS	STATUS/RESULTS
OXCARBAZEPINE	MED	evaluate effectiveness in slowing disease progression, also known as PROXIMUS study	possibly neuro-protective	oral	SP/60	Recruiting; read more https://clinicaltrials.gov/ct2/show/NCT02104661 . The National MS Society is funding a study of a possible biomarker for the success of neuroprotective therapies within this trial.
RITUXIMAB	MED	evaluate the safety and effectiveness of combined IV and intrathecal rituximab, also known as RIVITaLISe study	binds to CD20 antigen on B cells and induces B-cell breakdown	IV, intrathecal	SP/440	Terminated because of lack of efficacy of biomarkers. Read more http://clinicaltrials.gov/ct2/show/NCT01212094 .
RITUXIMAB	MED	evaluate the safety and effectiveness	binds to CD20 antigen on B cells and induces B-cell breakdown	intrathecal	SP,PP/12	Funded by the National MS Society jointly with other International Progressive MS Alliance members. Recruiting; read more https://clinicaltrials.gov/ct2/show/NCT02253264

AGENT	TYPE OF INTER-VENTION	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW THERAPY IS GIVEN	TYPE OF MS/NUMBER OF SUBJECTS	STATUS/RESULTS
RITUXIMAB WITH CEREBRAL MICRODIALYSIS	MED	test safety and effectiveness, and study immune messenger chemicals inside the brain	binds to CD20 antigen on B cells and induces B-cell lysis	intrathecal	SP,PP/20	Funded by the National MS Society jointly with other International Progressive MS Alliance members. Completed, awaiting publication of results. Read more https://clinicaltrials.gov/ct2/show/NCT01719159
SIMVASTATIN	MED	testing neuro-protection, also known as MS-STAT2	possibly neuro-protective	oral	SP/1180	Not yet recruiting. The Society is co-funding this trial in collaboration with other agencies and organizations.
SIPONIMOD	MED	evaluate safety and effectiveness	selective modulator of sphingosine-1-phosphate receptors	oral	SP, 1530	Recruiting, read more: http://clinicaltrials.gov/ct2/show/NCT01665144
STEM CELLS (AUTOLOGOUS BONE MARROW-DERIVED CELLULAR THERAPY)	MED	determine repair in progressive MS, also known as ACTiMuS Study	improve nerve impulse conduction	IV	Prog-ressive/80	Recruiting; read more https://clinicaltrials.gov/ct2/show/NCT01815632

AGENT	TYPE OF INTER-VENTION	PURPOSE OF STUDY	POSSIBLE MECHANISM	HOW THERAPY IS GIVEN	TYPE OF MS/NUMBER OF SUBJECTS	STATUS/RESULTS
TASK-ORIENTED UPPER LIMB TRAINING	REHAB	improve upper limb function	practicing tasks to acquire or reacquire a skill	Symbio Therapy or Tyromotion	SP,PP/98	Recruiting; read more https://clinicaltrials.gov/ct2/show/NCT02688231
TCELNA™ (IMILECLEUCE L-T, OPEXA THERAPEUTICS)	MED	determine effectiveness in reducing disability progression, also known as Abili-T study	experimental T-cell treatment made with a person's own immune cells (autologous T-cell immune-therapy)	SC	SP 180	Completed, did not meet primary endpoint, per company press release, October 28, 2016.
TESTOSTERONE	MED	reduce brain tissue volume loss	possibly neuro-protective	Trans-dermal	RR,SP,PP /114	Withdrawn, due to lack of funding, read more https://clinicaltrials.gov/ct2/show/NCT02317263
VIDEO GAME BASED TREATMENT	REHAB	improve arm strength	constraint-induced therapy based virtual reality intervention	computer gaming rehabilitation platform	PP/16	Completed; self-reported fatigue decreased significantly, motor speed did not significantly improve, large change in perceived quality of arm use for daily activities, per report from primary investigator.